Label: CRINONE- progesterone gel
-
Contains inactivated NDC Code(s)
NDC Code(s): 55056-0806-2, 55056-0808-6, 55056-0818-2, 55056-0818-5, view more55056-0818-9 - Packager: Columbia Laboratories, Inc.
- Category: HUMAN PRESCRIPTION DRUG LABEL
- DEA Schedule: None
- Marketing Status: New Drug Application
Drug Label Information
Updated November 19, 2009
If you are a consumer or patient please visit this version.
- Download DRUG LABEL INFO: PDF XML
- Official Label (Printer Friendly)
-
DESCRIPTION
Crinone® (progesterone gel) is a bioadhesive vaginal gel containing micronized progesterone in an emulsion system, which is contained in single use, one piece polyethylene vaginal applicators. The carrier vehicle is an oil in water emulsion containing the water swellable, but insoluble polymer, polycarbophil. The progesterone is partially soluble in both the oil and water phase of the vehicle, with the majority of the progesterone existing as a suspension. Physically, Crinone® has the appearance of a soft, white to off-white gel.
The active ingredient, progesterone, is present in either a 4% or an 8% concentration (w/w). The chemical name for progesterone is pregn-4-ene-3,20-dione. It has an empirical formula of C21H30O2 and a molecular weight of 314.5.
The structural formula is:
Progesterone exists in two polymorphic forms. Form 1, which is the form used in Crinone®, exists as white orthorhombic prisms with a melting point of 127-131°C.
Each applicator delivers 1.125 grams of Crinone® gel containing either 45 mg (4% gel) or 90 mg (8% gel) of progesterone in a base containing glycerin, mineral oil, polycarbophil, carbomer 934P, hydrogenated palm oil glyceride, sorbic acid, purified water and may contain sodium hydroxide.
-
CLINICAL PHARMACOLOGY
Progesterone is a naturally occurring steroid that is secreted by the ovary, placenta, and adrenal gland. In the presence of adequate estrogen, progesterone transforms a proliferative endometrium into a secretory endometrium. Progesterone is essential for the development of decidual tissue, and the effect of progesterone on the differentiation of glandular epithelia and stroma has been extensively studied. Progesterone is necessary to increase endometrial receptivity for implantation of an embryo. Once an embryo is implanted, progesterone acts to maintain the pregnancy. Normal or near-normal endometrial responses to oral estradiol and intramuscular progesterone have been noted in functionally agonadal women through the sixth decade of life. Progesterone administration decreases the circulatory levels of gonadotropins.
Pharmacokinetics
Absorption
Due to the sustained release properties of Crinone®, progesterone absorption is prolonged with an absorption half-life of approximately 25-50 hours, and an elimination half-life of 5-20 minutes. Therefore, the pharmacokinetics of Crinone® are rate-limited by absorption rather than by elimination.
The bioavailability of progesterone in Crinone® was determined relative to progesterone administered intramuscularly. In a single dose crossover study, 20 healthy, estrogenized postmenopausal women received 45 mg or 90 mg progesterone vaginally in Crinone® 4% or Crinone® 8%, or 45 mg or 90 mg progesterone intramuscularly. The pharmacokinetic parameters (mean ± standard deviation) are shown in Table 1.
TABLE 1 Single Dose Relative Bioavailability CRINONE® 4% 45 mg Intramuscular Progesterone CRINONE® 8% 90 mg Intramuscular Progesterone Cmax - maximum progesterone serum concentration
Cavg 0-24 - average progesterone serum concentration over 24 hours
AUC0-96 - area under the drug concentration versus time curve from 0-96 hours post dose
Tmax - time to maximum progesterone concentration
t1/2 - elimination half-life
F - relative bioavailabilityCmax (ng/mL) 13.15±6.49 39.06±13.68 14.87±6.32 53.76±14.9 Cavg 0-24 (ng/mL) 6.94±4.24 22.41±4.92 6.98±3.21 28.98±8.75 AUC0-96 (ng∙hr/mL) 288.63±273.72 806.26±102.75 296.78±129.90 1378.91±176.39 Tmax (hr) 5.6±1.84 8.2±6.43 6.8±3.3 9.2±2.7 t1/2 (hr) 55.13±28.04 28.05±16.87 34.8±11.3 19.6±6.0 F (%) 27.6 19.8 The multiple dose pharmacokinetics of Crinone® 4% and Crinone® 8% administered every other day and Crinone® 8% administered daily or twice daily for 12 days were studied in 10 healthy, estrogenized postmenopausal women in two separate studies. Steady state was achieved within the first 24 hours after initiation of treatment. The pharmacokinetic parameters (mean ± standard deviation) after the last administration of Crinone® 4% or 8% derived from these studies are shown in Table 2.
TABLE 2 Multiple Dose Pharmacokinetics Assisted Reproductive Technology Secondary Amenorrhea Daily Dosing 8% Twice Daily Dosing 8% Every Other Day Dosing 4% Every Other Day Dosing 8% Cmax (ng/mL) 15.97± 5.05 14.57 ± 4.49 13.21± 9.46 13.67 ± 3.58 Cavg (ng/mL) 8.99 ± 3.53 11.6 ± 3.47 4.05 ± 2.85 6.75 ± 2.83 Tmax (hr) 5.40 ± 0.97 3.55 ± 2.48 6.67 ± 3.16 7.00 ± 2.88 AUC0-t (ng∙hr/mL) 391.98 ±153.28 138.72 ± 41.58 242.15 ± 167.88 438.36 ± 223.36 t1/2 (hr) 45.00 ± 34.70 25.91 ± 6.15 49.87 ± 31.20 39.08 ± 12.88 Distribution
Progesterone is extensively bound to serum proteins (~96-99%), primarily to serum albumin and corticosteroid binding globulin.
Metabolism
The major urinary metabolite of oral progesterone is 5β-pregnan-3α, 20α-diol glucuronide which is present in plasma in the conjugated form only. Plasma metabolites also include 5β-pregnan-3α-ol-20-one (5β-pregnanolone) and 5α-pregnan-3α-ol-20-one (5α-pregnanolone).
Excretion
Progesterone undergoes both biliary and renal elimination. Following an injection of labeled progesterone, 50-60% of the excretion of progesterone metabolites occurs via the kidney; approximately 10% occurs via the bile and feces, the second major excretory pathway. Overall recovery of labeled material accounts for 70% of an administered dose, with the remainder of the dose not characterized with respect to elimination. Only a small portion of unchanged progesterone is excreted in the bile.
-
Clinical Studies
Assisted Reproductive Technology
In a single-center, open-label study (COL1620-007US), 99 women (aged 28-47 years) with either partial (n=84) or premature ovarian failure (n=15) who were candidates to receive a donor oocyte transfer as an Assisted Reproductive Technology ("ART") procedure were randomized to receive either Crinone® 8% twice daily (n=68) or intramuscular progesterone 100 mg daily (n=31). The study was divided into three phases (Pilot, Donor Egg and Treatment). The first phase of the study consisted of a test Pilot Cycle to ensure that the administration of transdermal estradiol and progesterone would adequately prime the endometrium to receive the donor egg. The second phase was the Donor Egg Cycle during which a fertilized oocyte was implanted. Crinone® 8% was administered beginning the evening of Day 14 of the Pilot and Donor Egg cycles. Subjects with partial ovarian function also underwent a Pre-Pilot Cycle and a Pre-Donor Egg Cycle during which time they were administered only leuprolide acetate to suppress remaining ovarian function. The Pre-Pilot Cycle, Pilot Cycle, Pre-Donor Egg Cycle, and Donor Egg Cycle each lasted approximately 34 days. The third phase of the study consisted of a 10-week treatment period to maintain a pregnancy until placental autonomy was achieved.
Sixty-one women received Crinone® 8% as part of the Pilot Cycle to determine their endometrial response. Of the 55 evaluable endometrial biopsies in the Crinone® 8% group performed on Day 25-27, all were histologically "in-phase", consistent with luteal phase biopsy specimens of menstruating women at comparable time intervals. Fifty-four women who received Crinone® 8% and had a histologically "in-phase" biopsy received a donor oocyte transfer. Among these 54 Crinone®-treated women, clinical pregnancies (assessed about week 10 after transfer by clinical examination, ultrasound and/or ß-hCG levels) occurred in 26 women (48%). Seventeen women (31%) delivered a total of 25 newborns, seven women (13%) had spontaneous abortions and two women (4%) had elective abortions.
In a second study (COL1620-F01), Crinone® 8% was used in luteal phase support of women with tubal or idiopathic infertility due to endometriosis and normal ovulatory cycles, undergoing in vitro fertilization ("IVF") procedures. All women received a GnRH analog to suppress endogenous progesterone, human menopausal gonadotropins, and human chorionic gonadotropin. In this multi-center, open-label study, 139 women (aged 22-38 years) received Crinone® 8% once daily beginning within 24 hours of embryo transfer and continuing through Day 30 post-transfer. Clinical pregnancies assessed at Day 90 post-transfer were seen in 36 (26%) of women. Thirty-two women (23%) delivered newborns and four women (3%) had spontaneous abortions. (See PRECAUTIONS, subsection Pregnancy)
Secondary Amenorrhea
In three parallel, open-label studies (COL1620-004US, COL1620-005US, COL1620-009US), 127 women (aged 18-44) with hypothalamic amenorrhea or premature ovarian failure were randomized to receive either Crinone® 4% (n=62) or Crinone® 8% (n=65). All women were treated with either conjugated estrogens 0.625 mg daily (n=100) or transdermal estradiol (delivering 50 mcg/day) twice weekly (n=27).
Estrogen therapy was continuous for the entire three 28-day cycle studies. At Day 15 of the second cycle (six weeks after initiating estrogen replacement), women who demonstrated adequate response to estrogen therapy (by ultrasound) and who continued to be amenorrheic received Crinone® every other day for six doses (Day 15 through Day 25 of the cycle).
In cycle 2, Crinone® 4% induced bleeding in 79% of women and Crinone® 8% induced bleeding in 77% of women. In the third cycle, estrogen was continued and Crinone® was administered every other day beginning on Day 15 for six doses. On Day 24 an endometrial biopsy was performed. In 53 women who received Crinone® 4%, biopsy results were as follows: 7% proliferative, 40% late secretory, 19% mid secretory, 13% early secretory, 7% atrophic, 6% menstrual endometrium, 6% inactive endometrium and 2% negative endometrium. In 54 women who received Crinone® 8%, biopsy results were as follows: 44% late secretory, 19% mid secretory, 11% early secretory, 19% atrophic, 5% menstrual endometrium and 2% "oral contraceptive like" endometrium.
- INDICATIONS AND USAGE
-
CONTRAINDICATIONS
Crinone® should not be used in individuals with any of the following conditions:
- Known sensitivity to Crinone® (progesterone or any of the other ingredients)
- Undiagnosed vaginal bleeding
- Liver dysfunction or disease
- Known or suspected malignancy of the breast or genital organs
- Missed abortion
- Active thrombophlebitis or thromboembolic disorders, or a history of hormone-associated thrombophlebitis or thromboembolic disorders
-
WARNINGS
The physician should be alert to the earliest manifestations of thrombotic disorders (thrombophlebitis, cerebrovascular disorders, pulmonary embolism, and retinal thrombosis). Should any of these occur or be suspected, the drug should be discontinued immediately.
Progesterone and progestins have been used to prevent miscarriage in women with a history of recurrent spontaneous pregnancy losses. No adequate evidence is available to show that they are effective for this purpose.
-
PRECAUTIONS
General
- The pretreatment physical examination should include special reference to breast and pelvic organs, as well as Papanicolaou smear.
- In cases of breakthrough bleeding, as in all cases of irregular vaginal bleeding, nonfunctional causes should be considered. In cases of undiagnosed vaginal bleeding, adequate diagnostic measures should be undertaken.
- Because progestogens may cause some degree of fluid retention, conditions which might be influenced by this factor (e.g., epilepsy, migraine, asthma, cardiac or renal dysfunction) require careful observation.
- The pathologist should be advised of progesterone therapy when relevant specimens are submitted.
- Patients who have a history of psychic depression should be carefully observed and the drug discontinued if the depression recurs to a serious degree.
- A decrease in glucose tolerance has been observed in a small percentage of patients on estrogen-progestin combination drugs. The mechanism of this decrease is not known. For this reason, diabetic patients should be carefully observed while receiving progestin therapy.
Information for Patients
The product should not be used concurrently with other local intravaginal therapy. If other local intravaginal therapy is to be used concurrently, there should be at least a 6-hour period before or after Crinone® administration. Small, white globules may appear as a vaginal discharge possibly due to gel accumulation, even several days after usage.
Carcinogenesis, Mutagenesis, Impairment of Fertility
Nonclinical toxicity studies to determine the potential of Crinone® to cause carcinogenicity or mutagenicity have not been performed. The effect of Crinone® on fertility has not been evaluated in animals.
Pregnancy
(See CLINICAL PHARMACOLOGY, subsection Clinical Studies)
Crinone® 8% has been used to support embryo implantation and maintain pregnancies through its use as part of ART treatment regimens in two clinical studies (studies COL1620-007US and COL1620-F01). In the first study (COL1620-007US), 54 Crinone®-treated women had donor oocyte transfer procedures, and clinical pregnancies occurred in 26 women (48%). The outcomes of these 26 pregnancies were as follows: one woman had an elective termination of pregnancy at 19 weeks due to congenital malformations (omphalocele) associated with a chromosomal abnormality; one woman pregnant with triplets had an elective termination of her pregnancy; seven women had spontaneous abortions; and 17 women delivered 25 apparently normal newborns.
In the second study (COL1620-F01), Crinone® 8% was used in the luteal phase support of women undergoing in vitro fertilization ("IVF") procedures. In this multi-center, open-label study, 139 women received Crinone® 8% once daily beginning within 24 hours of embryo transfer and continuing through Day 30 post-transfer.
Clinical pregnancies assessed at Day 90 post-transfer were seen in 36 (26%) of women. Thirty-two women (23%) delivered newborns and four women (3%) had spontaneous abortions. Of the 47 newborns delivered, one had a teratoma associated with a cleft palate; one had respiratory distress syndrome; 44 were apparently normal and one was lost to follow-up.
-
ADVERSE REACTIONS
Assisted Reproductive Technology
In a study of 61 women with ovarian failure undergoing a donor oocyte transfer procedure receiving Crinone® 8% twice daily, treatment-emergent adverse events occurring in 5% or more of the women are shown in Table 3.
TABLE 3 Treatment-Emergent Adverse Events in ≥5% of Women Receiving Crinone® 8% Twice Daily Study COL1620-007US (n=61) Body as a Whole Bloating 7% Cramps NOS 15% Pain 8% Central and Peripheral Nervous System Dizziness 5% Headache 13% Gastro-Intestinal System Nausea 7% Reproductive, Female Breast Pain 13% Moniliasis Genital 5% Vaginal Discharge 7% Skin and Appendages Pruritus Genital 5% In a second clinical study of 139 women using Crinone® 8% once daily for luteal phase support while undergoing an in vitro fertilization procedure, treatment-emergent adverse events reported in ≥5% of the women are shown in Table 4.
TABLE 4 Treatment-Emergent Adverse Events in ≥5% of Women Receiving Crinone® 8% Once Daily Study COL1620-F01 (n=139) Body as a Whole Abdominal Pain 12% Perineal Pain Female 17% Central and Peripheral Nervous System Headache 17% Gastro-Intestinal System Constipation 27% Diarrhea 8% Nausea 22% Vomiting 5% Musculo-Skeletal System Arthralgia 8% Psychiatric Depression 11% Libido Decreased 10% Nervousness 16% Somnolence 27% Reproductive, Female Breast Enlargement 40% Dyspareunia 6% Urinary System Nocturia 13% Secondary Amenorrhea
In three studies, 127 women with secondary amenorrhea received estrogen replacement therapy and Crinone® 4% or 8% every other day for six doses. Treatment emergent adverse events during estrogen and Crinone® treatment that occurred in 5% or more of women are shown in Table 5.
TABLE 5 Treatment-Emergent Adverse Events in ≥5% of Women Receiving Estrogen Treatment and Crinone® Every Other Day Studies COL1620-004US, COL1620-005US, COL1620-009US Estrogen + Crinone® 4%
n=62Estrogen + Crinone® 8%
n=65Body as a Whole Abdominal Pain 3 (5%) 6 (9%) Appetite Increased 3 (5%) 5 (8%) Bloating 8 (13%) 8 (12%) Cramps NOS 12 (19%) 17 (26%) Fatigue 13 (21%) 14 (22%) Central and Peripheral Nervous System Headache 12 (19%) 10 (15%) Gastro-Intestinal System Nausea 5 (8%) 4 (6%) Musculo-Skeletal System Back Pain 5 (8%) 2 (3%) Myalgia 5(8%) 0(0%) Psychiatric Depression 12 (19%) 10 (15%) Emotional Lability 14 (23%) 14 (22%) Sleep Disorder 11 (18%) 12 (18%) Reproductive, Female Vaginal Discharge 7 (11%) 2 (3%) Resistance Mechanism Upper Respiratory Tract Infection 3 (5%) 5 (8%) Skin and Appendages Pruitis genital 1 (2%) 4 (6%) Additional adverse events reported in women at a frequency <5% in Crinone® ART and secondary amenorrhea studies and not listed in the tables above include:
Autonomic Nervous System–mouth dry, sweating increased
Body as a Whole–abnormal crying, allergic reaction, allergy, appetite decreased, asthenia, edema, face edema, fever, hot flushes, influenza-like symptoms, water retention, xerophthalmia
Cardiovascular, General–syncope
Central and Peripheral Nervous System–migraine, tremor
Gastro-Intestinal–dyspepsia, eructation, flatulence, gastritis, toothache
Metabolic and Nutritional–thirst
Musculo-Skeletal System–cramps legs, leg pain, skeletal pain
Neoplasm–benign cyst
Platelet, Bleeding & Clotting–purpura
Psychiatric–aggressive reactions, forgetfulness, insomnia
Red Blood Cell–anemia
Reproductive, Female–dysmenorrhea, premenstrual tension, vaginal dryness
Resistance Mechanism–infection, pharyngitis, sinusitis, urinary tract infection
Respiratory System–asthma, dyspnea, hyperventilation, rhinitis
Skin and Appendages–acne, pruritis, rash, seborrhea, skin discoloration, skin disorder, urticaria
Urinary System–cystitis, dysuria, micturition frequency
Vision Disorders–conjunctivitis
- OVERDOSAGE
-
DOSAGE AND ADMINISTRATION
Assisted Reproductive Technology
Crinone® 8% is administered vaginally at a dose of 90 mg once daily in women who require progesterone supplementation. Crinone® 8% is administered vaginally at a dose of 90 mg twice daily in women with partial or complete ovarian failure who require progesterone replacement. If pregnancy occurs, treatment may be continued until placental autonomy is achieved, up to 10-12 weeks.
Secondary Amenorrhea
Crinone® 4% is administered vaginally every other day up to a total of six doses. For women who fail to respond, a trial of Crinone® 8% every other day up to a total of six doses may be instituted.
It is important to note that a dosage increase from the 4% gel can only be accomplished by using the 8% gel. Increasing the volume of gel administered does not increase the amount of progesterone absorbed.
SEE Crinone® PATIENT INFORMATION SHEET - HOW TO USE Crinone® .
Note: The PATIENT INFORMATION SHEET contains special instructions for using the applicator at altitudes above 2500 feet in order to avoid a partial release of Crinone® before vaginal insertion.
-
HOW SUPPLIED
Crinone® is available in the following strengths:
4% gel (45 mg) in a single use, one piece, disposable, white polyethylene vaginal applicator with a twist-off top. Each applicator contains 1.45 g of gel and delivers 1.125 g of gel.
NDC-55056-0808-6 - 6 Single-use prefilled applicators.
8% gel (90 mg) in a single use, one piece, disposable, white polyethylene vaginal applicator with a twist-off top. Each applicator contains 1.45 g of gel and delivers 1.125 g of gel.
NDC-55056-0806-2 - 6 Single-use prefilled applicators
NDC-55056-0818-5 - 15 Single-use prefilled applicators
NDC-55056-0818-2 - 18 Single-use prefilled applicatorsEach applicator is wrapped and sealed in a foil overwrap.
- SPL UNCLASSIFIED SECTION
-
PATIENT INFORMATION
Crinone® 8%
(progesterone gel)
For Vaginal Use OnlyFOR PROGESTERONE SUPPLEMENTATION OR REPLACEMENT AS PART OF AN ASSISTED REPRODUCTIVE TECHNOLOGY ("ART") TREATMENT FOR INFERTILE WOMEN WITH PROGESTERONE DEFICIENCY
Please read this information carefully before you start to use Crinone® and each time your prescription is renewed, in case anything has changed. This leaflet does not take the place of discussions with your doctor. If you still have any questions, ask your doctor or health-care provider.
What Crinone® is
Crinone® is a specially formulated gel that you insert in your vagina. It contains the natural female hormone called progesterone. Crinone® 8% is used as part of a program for women who are undergoing fertility treatment.
Understanding the role of Crinone® in your infertility treatment
Progesterone is one of the hormones essential for maintaining a pregnancy. If you are undergoing ART treatment and your doctor has determined your body does not produce enough progesterone on its own, Crinone® may be prescribed to provide the progesterone you need.
The progesterone in Crinone® will help prepare the lining of your uterus so that it is ready to receive and nourish a fertilized egg. If pregnancy occurs, Crinone® may be supplemented for 10-12 weeks until production of progesterone by the placenta is adequate.
When you should not use Crinone®
- If you are allergic to progesterone, progesterone-like drugs, or any of the inactive ingredients in the gel (ask a pharmacist if you are not sure about the inactive ingredients in Crinone®
- If you have unusual vaginal bleeding which has not been evaluated by a doctor.
- If you have a liver disease.
- If you have known or suspected cancer of the breast or genital organs.
- If you have a miscarriage and your physician suspects some tissue is still in the uterus.
- If you have or have had blood clots in the legs, lungs, eyes, or elsewhere.
Risks of Crinone®
- Risk to the fetus. Birth defects have been reported in the offspring of women who were using Crinone® during early pregnancy. These included an abdominal wall defect and a cleft palate. A causal association has been neither confirmed nor refuted. You should check with your doctor about the risks to your unborn child of any medication used during pregnancy.
- Blood clots and related health problems. Blood clots have been reported with the use of estrogens and progestational drugs (alone or in combination). If blood clots do form in your bloodstream, they can cut off the blood supply to vital organs, causing serious problems. These problems may include a stroke (by cutting off blood to part of the brain), a heart attack (by cutting off blood to part of the heart), a pulmonary embolus (by cutting off blood to part of the lungs), or other problems. Any of these conditions may cause death or serious long-term disability. Call your doctor immediately if you suspect you have any of these conditions. He or she may advise you to stop using this drug.
PRECAUTIONS
Be alert for unusual signs and symptoms. If any of these warning signals (or any other unusual symptoms) happen while you are using Crinone®, call your doctor immediately:
- Abnormal bleeding from the vagina.
- Pains in the calves or chest, a sudden shortness of breath or coughing blood indicating possible clots in the legs, heart, or lungs.
- Severe headache or vomiting, dizziness, faintness, or changes in vision or speech, weakness or numbness of an arm or leg indicating possible clots in the brain or eye.
- Breast lumps, which could be associated with fibrocystic disorders, fibroadenoma, or breast cancer. (Ask your doctor or health-care provider to show you how to examine your breasts monthly.)
- Yellowing of the skin and/or white of the eyes indicating possible liver problems.
You should also notify your doctor if you experience depression, worsening of your diabetic condition, or fluid retention.
Possible side effects of Crinone®
In addition to the risks listed above, the following side effects have been reported with Crinone® used either for progesterone supplementation or for replacement as part of an ART treatment for infertile women with progesterone deficiency. Consult your doctor if you experience any of the side effects mentioned below, or other side effects.
SIDE EFFECTS REPORTED AT A FREQUENCY OF 5% OR GREATER
- abdominal pain; perineal pain (the perineum is the area between the vagina and the rectum)
- headache
- constipation; diarrhea; nausea
- joint pain
- depression; decreased libido; nervousness; sleepiness1
- breast enlargement
- excessive urination at night
SIDE EFFECTS REPORTED AT A FREQUENCY RANGING FROM 1% TO 5%
- allergy; bloating; cramps; fatigue; pain
- dizziness1
- vomiting
- mood swings
- breast pain
- difficult or painful intercourse; genital itching; genital yeast infection; vaginal discharge
- urinary tract infection
SIDE EFFECTS REPORTED AT A FREQUENCY OF LESS THAN 1%
- fever; flu-like symptoms
- water retention2
- gastrointestinal discomfort; gas; abdominal swelling
- back pain; leg pain
- insomnia
- sinusitis; upper respiratory tract infection
- asthma
- acne; itching
- painful or difficult urination; frequent urination
How Crinone® works
Crinone® has been formulated to be administered through the vagina. The moisturizing gel in Crinone® forms a coating on the walls of the vagina which allows for absorption of progesterone through the vaginal tissue. Small, white globules may appear as a vaginal discharge possibly due to gel accumulation, even several days after usage. Crinone® contains no irritating perfumes or dyes.
Other information
- Your doctor has prescribed this drug for you and you alone. Do not give this drug to anyone else.
- This medication was prescribed for your particular medical condition. Do not use it for another condition.
- Keep this and all drugs out of the reach of children.
How to use Crinone®
The dosage is one application of the 8% gel (90 mg of progesterone) vaginally, daily or twice daily as directed by your doctor. If you become pregnant, your doctor may decide to continue treatment for up to 10 to 12 weeks.
Crinone® is to be applied directly from the specially designed sealed applicator into the vagina. The applicator is designed to deliver a premeasured dose of Crinone®. A small amount of gel will be left in the tube after usage. Do not be concerned because you will still be receiving the appropriate, measured dosage.
Under certain rare circumstances, such as high altitude, brief exposure to high temperature, sudden changes in atmospheric/barometric pressure, and pressure controlled environments such as airplanes or high-rise buildings, the internal pressure of the applicator may become higher than the air pressure. This imbalance between the internal and external pressure may cause the gel to expel from the applicator when the twist-off tab is removed. If you should experience the gel expelling from the applicator upon opening, please follow the SPECIAL INSTRUCTIONS FOR USE AT ALTITUDES ABOVE 2500 FEET.
- Remove the applicator from the sealed wrapper. DO NOT remove the twist-off tab at this time. For use at altitudes above 2500 feet, see special instructions below.
- Hold the applicator between the thumb and forefinger along the seam on the sides of the bulb. Shake down vigorously 3 to 4 times (like a thermometer) to ensure that the contents are at the thin end of the applicator.
- Hold the applicator by the flat section of the bulb. Twist off the tab at the thin end and throw away. DO NOT squeeze the bulb while twisting the tab. This could force some gel to be released before it is inserted.
Twist off completely – Do not pull off - The applicator may be inserted into the vagina while you are in a sitting position or when lying on your back with your knees bent. Gently insert the thin end well into the vagina.
- Squeeze the bulb of the applicator to deposit the gel into the vagina. Remove the applicator and throw it away in a waste container. Do not be concerned if a small amount of gel is left in the applicator. You will still be receiving the appropriate, measured dosage.
SPECIAL INSTRUCTIONS FOR USE AT ALTITUDES ABOVE 2500 FEET
- Remove the applicator from the sealed wrapper. DO NOT remove the twist-off tab at this time. Hold the applicator on both sides of the bulb, as shown. Using a lancet or a stick pin, make a single puncture in the flat part of the bulb. This will relieve the difference in air pressure between the inside and outside of the applicator caused by high altitudes. It will not affect the amount of gel administered. You will still be receiving the appropriate, measured dosage.
- See Step 2 above.
- See Step 3 above.
- See Step 4 above.
- Place your thumb or finger over the puncture that you made in the bulb of the applicator. Squeeze the bulb of the applicator to deposit the gel into the vagina. Remove the applicator and throw it away in a waste container. Do not be concerned if a small amount of gel is left in the applicator. You will still be receiving the appropriate, measured dosage.
Crinone® coats the vaginal lining to provide long-lasting release of progesterone. Small, white globules may appear as a vaginal discharge possibly due to gel accumulation, even several days after usage. It is not unusual, but if you are concerned, discuss this with your doctor.
If you forget a dose of Crinone®, use it as soon as you remember, but do not use more than the recommended daily dose. Crinone® should not be used at the same time that you are using other vaginal therapy.
This leaflet provides the most important information about Crinone®. If you want to read more, ask your doctor or pharmacist about the professional leaflet. You may need their help to understand some of the information.
How Supplied
Crinone® is available as 8% gel (90 mg of progesterone).
Each box of the 8% gel contains either six, fifteen, or eighteen single use, disposable vaginal applicators with a twist-off tab. Each applicator is wrapped and sealed in a foil overwrap.
Crinone® should be stored at 25°C (77°F); excursions permitted to 15-30°C (59-86°F).
Do not use Crinone® after the expiration date which is printed on the box.
Manufactured for: Columbia Laboratories, Inc., Livingston, NJ 07039
Manufactured by: Fleet Laboratories Ltd., Watford, United Kingdom
Revised May 2009
PATIENT INFORMATION
Crinone® 4% and 8% (progesterone gel)
For Vaginal Use OnlyFOR THE TREATMENT OF SECONDARY AMENORRHEA (ABSENCE OF MENSES IN WOMEN WHO HAVE PREVIOUSLY HAD A MENSTRUAL PERIOD)
Please read this information carefully before you start to use Crinone® and each time your prescription is renewed, in case anything has changed. This leaflet does not take the place of discussions with your doctor. If you still have any questions, ask your doctor or health-care provider.
What Crinone® is
Crinone® is a specially formulated gel that you insert in your vagina. It contains the natural female hormone called progesterone. The 4% gel is used for women whose menstrual cycle has stopped. The 8% gel is to be used when the 4% gel has not worked.
Understanding the role of Crinone® in the treatment of your menstrual irregularities
Progesterone is one of the hormones essential for regular menstrual periods. If your doctor has determined your body does not produce enough progesterone on its own, Crinone® may be prescribed to provide the progesterone you need.
When you do not produce enough progesterone, menstrual irregularities can occur. Crinone® can provide you with the progesterone needed during a normal menstrual cycle.
When you should not use Crinone®
- If you are allergic to progesterone, progesterone-like drugs, or any of the inactive ingredients in the gel (ask a pharmacist if you are not sure about the inactive ingredients in Crinone®).
- If you have unusual vaginal bleeding which has not been evaluated by a doctor.
- If you have a liver disease.
- If you have known or suspected cancer of the breast or genital organs.
- If you have a miscarriage and your physician suspects some tissue is still in the uterus.
- If you have or have had blood clots in the legs, lungs, eyes, or elsewhere.
Risks of Crinone®
- Risk to the fetus. Birth defects have been reported in the offspring of women who were using Crinone® during early pregnancy. These included an abdominal wall defect and a cleft palate. A causal association has been neither confirmed nor refuted. You should check with your doctor about the risks to your unborn child of any medication used during pregnancy.
- Blood clots and related health problems. Blood clots have been reported with the use of estrogens and progestational drugs (alone or in combination). If blood clots do form in your bloodstream, they can cut off the blood supply to vital organs, causing serious problems. These problems may include a stroke (by cutting off blood to part of the brain), a heart attack (by cutting off blood to part of the heart), a pulmonary embolus (by cutting off blood to part of the lungs), or other problems. Any of these conditions may cause death or serious long-term disability. Call your doctor immediately if you suspect you have any of these conditions. He or she may advise you to stop using this drug.
PRECAUTIONS
Be alert for unusual signs and symptoms. If any of these warning signals (or any other unusual symptoms) happen while you are using Crinone®, call your doctor immediately:
- Abnormal bleeding from the vagina.
- Pains in the calves or chest, a sudden shortness of breath or coughing blood indicating possible clots in the legs, heart, or lungs.
- Severe headache or vomiting, dizziness, faintness, or changes in vision or speech, weakness or numbness of an arm or leg indicating possible clots in the brain or eye.
- Breast lumps, which could be associated with fibrocystic disorders, fibroadenoma, or breast cancer. (Ask your doctor or health-care provider to show you how to examine your breasts monthly.)
- Yellowing of the skin and/or white of the eyes indicating possible liver problems.
You should also notify your doctor if you experience depression, worsening of your diabetic condition, or fluid retention.
Possible side effects of Crinone®
In addition to the risks listed above, the following side effects have been reported in studies with Crinone® used for the treatment of menstrual irregularities due to progesterone deficiency. In these studies, women were treated with estrogen prior to and during Crinone® therapy. All side effects reported at a frequency of 5% or greater after Crinone® was added to estrogen therapy also were reported with estrogen therapy alone. Consult your doctor if you experience any of the side effects mentioned below, or other side effects.
SIDE EFFECTS REPORTED AT A FREQUENCY OF 5% OR GREATER
- abdominal pain; increased appetite; bloating; cramps; fatigue
- headache
- nausea
- back pain
- depression; mood swings; sleep disorder
- vaginal discharge
- upper respiratory tract infection
SIDE EFFECTS REPORTED AT A FREQUENCY RANGING FROM 1% TO 5%
- increased sweating
- allergy; flu-like symptoms; hot flushes; pain
- dizziness1
- migraine; tremor
- gas; gastrointestinal discomfort
- thirst
- leg pain; muscle pain
- insomnia; nervousness; sleepiness1
- breast pain; painful menstruation
- infection; genital yeast infection
- acne; genital itching; rash; skin disorder
- frequent urination
SIDE EFFECTS REPORTED AT A FREQUENCY OF LESS THAN 1%
- dry mouth
- abnormal crying; allergic reaction; decreased appetite; dry eyes; swelling; face swelling; perineal pain (the perineum is the area between the vagina and the rectum); water retention2; weakness
- fainting
- abdominal swelling; gastritis; toothache
- joint pain; leg cramps; skeletal pain
- non-cancerous cyst
- bruising
- aggressive reaction; forgetfulness
- anemia
- premenstrual syndrome; vaginal dryness
- sore throat
- rapid, shallow breathing; shortness of breath; runny nose
- hives; itching; oily or dry scaly skin; skin discoloration
- bladder inflammation; painful or difficult urination
- "pink eye"
How Crinone® works
Crinone® has been formulated to be administered through the vagina. The moisturizing gel in Crinone® forms a coating on the walls of the vagina which allows for absorption of progesterone through the vaginal tissue. Small, white globules may appear as a vaginal discharge possibly due to gel accumulation, even several days after usage. Crinone® contains no irritating perfumes or dyes.
Other information
- Your doctor has prescribed this drug for you and you alone. Do not give this drug to anyone else.
- This medication was prescribed for your particular medical condition. Do not use it for another condition.
- Keep this and all drugs out of the reach of children.
How to use Crinone®
The dosage is one application of the 4% gel (45 mg of progesterone), vaginally, every other day as directed by your doctor, for a total of six doses. In some cases, your doctor may prescribe the 8% gel (90 mg of progesterone) every other day, for a total of six doses.
It is important to note that a dosage increase from the 4% gel can only be accomplished by using the 8% gel. Increasing the volume of gel administered does not increase the amount of progesterone absorbed.
Crinone® is to be applied directly from the specially designed sealed applicator into the vagina. The applicator is designed to deliver a premeasured dose of Crinone®. A small amount of gel will be left in the tube after usage. Do not be concerned because you will still be receiving the appropriate, measured dosage.
Under certain rare circumstances, such as high altitude, brief exposure to high temperature, sudden changes in atmospheric/barometric pressure, and pressure controlled environments such as airplanes or high-rise buildings, the internal pressure of the applicator may become higher than the air pressure. This imbalance between the internal and external pressure may cause the gel to expel from the applicator when the twist-off tab is removed. If you should experience the gel expelling from the applicator upon opening, please follow the SPECIAL INSTRUCTIONS FOR USE AT ALTITUDES ABOVE 2500 FEET.
- Remove the applicator from the sealed wrapper. DO NOT remove the twist-off tab at this time. For use at altitudes above 2500 feet, see special instructions below.
- Hold the applicator between the thumb and forefinger along the seam on the sides of the bulb. Shake down vigorously 3 to 4 times (like a thermometer) to ensure that the contents are at the thin end of the applicator.
- Hold the applicator by the flat section of the bulb. Twist off the tab at the thin end and throw away. DO NOT squeeze the bulb while twisting the tab. This could force some gel to be released before it is inserted.
Twist off completely – Do not pull off - The applicator may be inserted into the vagina while you are in a sitting position or when lying on your back with your knees bent. Gently insert the thin end well into the vagina.
- Squeeze the bulb of the applicator to deposit the gel into the vagina. Remove the applicator and throw it away in a waste container. Do not be concerned if a small amount of gel is left in the applicator. You will still be receiving the appropriate, measured dosage.
SPECIAL INSTRUCTIONS FOR USE AT ALTITUDES ABOVE 2500 FEET
- Remove the applicator from the sealed wrapper. DO NOT remove the twist-off tab at this time. Hold the applicator on both sides of the bulb, as shown. Using a lancet or a stick pin, make a single puncture in the flat part of the bulb. This will relieve the difference in air pressure between the inside and outside of the applicator caused by high altitudes. It will not affect the amount of gel administered. You will still be receiving the appropriate, measured dosage.
- See Step 2 above.
- See Step 3 above.
- See Step 4 above.
- Place your thumb or finger over the puncture that you made in the bulb of the applicator. Squeeze the bulb of the applicator to deposit the gel into the vagina. Remove the applicator and throw it away in a waste container. Do not be concerned if a small amount of gel is left in the applicator. You will still be receiving the appropriate, measured dosage.
Crinone® coats the vaginal lining to provide long-lasting release of progesterone. Small, white globules may appear as a vaginal discharge possibly due to gel accumulation, even several days after usage. It is not unusual, but if you are concerned, discuss this with your doctor.
If you forget a dose of Crinone®, use it as soon as you remember, but do not use more than the recommended daily dose. Crinone® should not be used at the same time that you are using other vaginal therapy.
This leaflet provides the most important information about Crinone®. If you want to read more, ask your doctor or pharmacist about the professional leaflet. You may need their help to understand some of the information.
How Supplied
Crinone® is available in two strengths: 4% gel (45 mg of progesterone) and 8% gel (90 mg of progesterone).
Each box of the 4% gel contains six single use, disposable vaginal applicators with a twist-off tab. Each box of the 8% gel contains either six , fifteen, or eighteen single use, disposable vaginal applicators with a twistoff tab. Each applicator is wrapped and sealed in a foil overwrap.
Crinone® should be stored at 25°C (77°F); excursions permitted to 15-30°C (59-86°F).
Do not use Crinone® after the expiration date which is printed on the box.
Manufactured for: Columbia Laboratories, Inc., Livingston, NJ 07039
Manufactured by: Fleet Laboratories Ltd., Watford, United Kingdom
Revised May 2009
- PRINCIPAL DISPLAY PANEL - 15 Single-Use Prefilled Applicator Carton
-
INGREDIENTS AND APPEARANCE
CRINONE
progesterone gelProduct Information Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:55056-0808 Route of Administration VAGINAL Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength progesterone (UNII: 4G7DS2Q64Y) (progesterone - UNII:4G7DS2Q64Y) progesterone 45 mg in 1.125 g Inactive Ingredients Ingredient Name Strength glycerin (UNII: PDC6A3C0OX) mineral oil (UNII: T5L8T28FGP) polycarbophil (UNII: W25LM17A4W) carbomer 934 (UNII: Z135WT9208) palm oil (UNII: 5QUO05548Z) sorbic acid (UNII: X045WJ989B) water (UNII: 059QF0KO0R) sodium hydroxide (UNII: 55X04QC32I) Packaging # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC:55056-0808-6 6 in 1 CARTON 1 1.125 g in 1 APPLICATOR Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date NDA NDA020701 05/13/1997 CRINONE
progesterone gelProduct Information Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:55056-0806 Route of Administration VAGINAL Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength progesterone (UNII: 4G7DS2Q64Y) (progesterone - UNII:4G7DS2Q64Y) progesterone 90 mg in 1.125 g Inactive Ingredients Ingredient Name Strength glycerin (UNII: PDC6A3C0OX) mineral oil (UNII: T5L8T28FGP) polycarbophil (UNII: W25LM17A4W) carbomer 934 (UNII: Z135WT9208) palm oil (UNII: 5QUO05548Z) sorbic acid (UNII: X045WJ989B) water (UNII: 059QF0KO0R) sodium hydroxide (UNII: 55X04QC32I) Packaging # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC:55056-0806-2 6 in 1 CARTON 1 1.125 g in 1 APPLICATOR Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date NDA NDA020701 05/13/1997 CRINONE
progesterone gelProduct Information Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:55056-0818 Route of Administration VAGINAL Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength progesterone (UNII: 4G7DS2Q64Y) (progesterone - UNII:4G7DS2Q64Y) progesterone 90 mg in 1.125 g Inactive Ingredients Ingredient Name Strength glycerin (UNII: PDC6A3C0OX) mineral oil (UNII: T5L8T28FGP) polycarbophil (UNII: W25LM17A4W) carbomer 934 (UNII: Z135WT9208) palm oil (UNII: 5QUO05548Z) sorbic acid (UNII: X045WJ989B) water (UNII: 059QF0KO0R) sodium hydroxide (UNII: 55X04QC32I) Packaging # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC:55056-0818-2 18 in 1 CARTON 1 1.125 g in 1 APPLICATOR 2 NDC:55056-0818-5 15 in 1 CARTON 2 1.125 g in 1 APPLICATOR 3 NDC:55056-0818-9 2 in 1 CARTON 3 1.125 g in 1 APPLICATOR Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date NDA NDA020701 05/13/1997 Labeler - Columbia Laboratories, Inc. (177253754) Establishment Name Address ID/FEI Business Operations Columbia Laboratories Inc 177253754 REPACK
